WO2026047641 - MACROCYCLIC COMPOUNDS AS RAS INHIBITORS FOR THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2026/047641
Publication Date
05.03.2026
International Application No.
PCT/IB2025/058838
International Filing Date
02.09.2025
Title **
[English]
MACROCYCLIC COMPOUNDS AS RAS INHIBITORS FOR THE TREATMENT OF CANCER
[French]
COMPOSÉS MACROCYCLIQUES EN TANT QU'INHIBITEURS DE RAS POUR LE TRAITEMENT DU CANCER
Applicants **
SUNRISE ONCOLOGY (HONG KONG) LIMITED
Inventors
TONG, Xiaotian
ZHOU, Wenbo
CHEN, Huang
LU, Jian
PENG, Shihong
LIU, Mingyao
Priority Data
PCT/CN2024/116363
02.09.2024
CN
PCT/CN2025/092141
29.04.2025
CN
PCT/CN2025/110667
25.07.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4274 | |
| EPO | Filing, Examination, Granting | 19850 | |
| Japan | Filing, Examination, Granting | 2418 | |
| South Korea | Filing, Examination, Granting | 2610 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
37,492
Contact Us
Abstract[English]
The present invention is related to a compound, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a metabolite thereof, a prodrug thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt, wherein the compound has a structure according to formula (I), and its use for the treatment of cancer.[French]
La présente invention concerne un composé, ou un stéréoisomère de celui-ci, un sel pharmaceutiquement acceptable de celui-ci, un métabolite de celui-ci, un promédicament de celui-ci, un solvate de celui-ci, ou un solvate du sel pharmaceutiquement acceptable, le composé présentant une structure selon la formule (I), et son utilisation pour le traitement du cancer.